Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | The need for biomarkers to aid in treatment decision making for upper tract urothelial carcinoma

Janet Kukreja • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer

Janet Kukreja, MD, MPH, University of Colorado, Boulder, CO, outlines the requirement for biomarkers in upper tract urothelial carcinoma (UTUC) due to the difficulties in making a correct diagnosis for different types of UTUC tumors. Historically, UTUC has been treated as bladder cancer despite being gnomically different. The discovery of UTUC biomarkers would aid in the differentiation of treatment and the personalization of medicine. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Janet Kukreja

Recent advances in the treatment of upper tract urothelial carcinoma
1:17
Recent advances in the treatment of upper tract urothelial carcinoma
Janet Kukreja • 18 Feb 2022
Robotic surgery for patients with upper tract urothelial carcinoma
0:45
Robotic surgery for patients with upper tract urothelial carcinoma
Janet Kukreja • 18 Feb 2022
Unmet needs for patients with upper tract urothelial carcinoma
1:07
Unmet needs for patients with upper tract urothelial carcinoma
Janet Kukreja • 18 Feb 2022

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals